Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.
340B stakeholders will be paying close attention to comments on how Medicare Part B should make hospitals whole for five years of what 340B hospitals argue are illegal underpayments for 340B-purchased drugs. The Centers for Medicare & Medicaid Services (CMS) reduced Part B reimbursement for 340B drugs in 2018 from average sales price plus 6% to ASP minus 22.5%. The U.S. Supreme Court declared the reductions illegal in June but only ruled on the 2018 and 2019 fiscal years. Hospital groups and CMS are sparring in federal district court in Washington, D.C., over how 340B hospitals should be repaid and whether the repayments will span the entire five year period.
Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
